Title:
ANTI-CANCER AGENT-BONDED ALGINIC ACID DERIVATIVE
Document Type and Number:
WIPO Patent Application WO/2019/189419
Kind Code:
A1
Abstract:
A compound that can be used as a sustained-release preparation capable of releasing an active ingredient sustainably and stably in a living body is provided using alginic acid as a base material that can become a choice for a novel base material.
The present invention relates to an alginic acid derivative having such a structure that alginic acid or a salt thereof is covalently bonded to a camptothecin derivative through a linker, preferably an alginic acid derivative having a structure represented by the formula: (A)-L-(D) (wherein (A) represents one residue that is derived from alginic acid or a salt thereof and has a C(=O)- group in either one monosaccharide selected from L-guluronic acid and D-mannuronic acid both constituting alginic acid; (D) represents a group formed by removing a hydrogen atom from a hydroxyl group in the camptothecin derivative; and L represents a linker that has a functional group capable of bonding to (A) through an amide bond and also has a functional group capable of bonding to (D) through an ester bond).
More Like This:
Inventors:
NARUMI TOMOHIRO (JP)
Application Number:
PCT/JP2019/013286
Publication Date:
October 03, 2019
Filing Date:
March 27, 2019
Export Citation:
Assignee:
MOCHIDA PHARM CO LTD (JP)
International Classes:
C08B37/04; A61K9/08; A61K31/4745; A61K47/61; A61P35/00
Foreign References:
| JPH1095802A | 1998-04-14 | |||
| JPH1171280A | 1999-03-16 | |||
| JP2001504453A | 2001-04-03 | |||
| JP2002539132A | 2002-11-19 | |||
| JP2014532733A | 2014-12-08 | |||
| JP2003527443A | 2003-09-16 | |||
| JPH0824325A | 1996-01-30 | |||
| JPH1072467A | 1998-03-17 | |||
| CN101745119A | 2010-06-23 | |||
| CN103705940A | 2014-04-09 |
Other References:
"The Practice of Medicinal Chemistry", 25 September 1999, pages: 321 - 338
Attorney, Agent or Firm:
TANAKA Shinichiro et al. (JP)
Download PDF: